Seungtaek Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seungtaek Kim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Sang Hoon Ahn
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, The Republic of Korea
4 shared publications Bora Jin
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3 shared publications- Kwang-Hyub Han
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications Aeri Chung
Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
1 shared publicationDo Young Kim
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
1 shared publicationHye Jung Park
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 15 December 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-7
Effect of S267F variant of NTCP on the patients with chronic hepatitis B
Sodium taurocholate cotransporting polypeptide (NTCP) was identified as an entry receptor for hepatitis B virus (HBV) infection. The substitution of serine at position 267 of NTCP with phenylalanine (S267F) is an Asian-specific variation that hampers HBV entry in vitro. In this study, we aimed to evaluate the prevalence of S267F polymorphism in Korean patients with chronic hepatitis B (CHB) and its association with disease progression and potential viral evolution in the preS1 domain of HBV. We found that the frequency of the S267F variant of NTCP in CHB patients and controls was 2.7% and 5.7% (P = 0.031), respectively, and that those who had S267F variant were less susceptible to chronic HBV infection. The frequency of the S267F variant in CHB, cirrhosis and hepatocellular carcinoma (HCC) patients was 3.3%, 0.9%, and 3.5%, respectively. Thus, the S267F variant correlated significantly with a lower risk for cirrhosis (P = 0.036). Sequencing preS1 domain of HBV from the patients who had S267F variant revealed no significant sequence change compared to the wild type. In conclusion, the S267F variant of NTCP is clinically associated with a lower risk of chronic HBV infection and cirrhosis development, which implicates suppressing HBV entry could reduce the disease burden.
- 15 December 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-7
Open AccessEffect of S267F variant of NTCP on the patients with chronic hepatitis B
Sodium taurocholate cotransporting polypeptide (NTCP) was identified as an entry receptor for hepatitis B virus (HBV) infection. The substitution of serine at position 267 of NTCP with phenylalanine (S267F) is an Asian-specific variation that hampers HBV entry in vitro. In this study, we aimed to evaluate the prevalence of S267F polymorphism in Korean patients with chronic hepatitis B (CHB) and its association with disease progression and potential viral evolution in the preS1 domain of HBV. We found that the frequency of the S267F variant of NTCP in CHB patients and controls was 2.7% and 5.7% (P = 0.031), respectively, and that those who had S267F variant were less susceptible to chronic HBV infection. The frequency of the S267F variant in CHB, cirrhosis and hepatocellular carcinoma (HCC) patients was 3.3%, 0.9%, and 3.5%, respectively. Thus, the S267F variant correlated significantly with a lower risk for cirrhosis (P = 0.036). Sequencing preS1 domain of HBV from the patients who had S267F variant revealed no significant sequence change compared to the wild type. In conclusion, the S267F variant of NTCP is clinically associated with a lower risk of chronic HBV infection and cirrhosis development, which implicates suppressing HBV entry could reduce the disease burden.
- Open Access
- 15 November 2016
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 10 (6) , 890-895
Hepatitis C Virus and Antiviral Drug Resistance
Seungtaek Kim, Kwang-Hyub Han, and Sang Hoon Ahn. Gut and Liver 2016;10:890-5. https://doi.org/10.5009/gnl15573
- 15 November 2016
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 10 (6) , 890-895
Open AccessHepatitis C Virus and Antiviral Drug Resistance
Seungtaek Kim, Kwang-Hyub Han, and Sang Hoon Ahn. Gut and Liver 2016;10:890-5. https://doi.org/10.5009/gnl15573
- 8 June 2016
- Published by Wiley in Journal of Medical Virology
- Vol. 89 (1) , 146-152
Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes
Most of HCV RNAs require cell culture-adaptive mutations for efficient replication in cell culture and a number of such mutations have been described including a well-known S2204I substitution mutation in NS5A protein. In contrast, the replication of genotype 2a JFH1 RNA in cell culture does not require any cell culture-adaptive mutation. Rather, the presence of S2204I mutation impaired the JFH1 RNA replication. In this study, we examined the effect of reversions and substitutions of NS5A cell culture-adaptive mutations on virus replication in different genotypic backgrounds after either placing genotype 1a NS5A in the genotype 2a JFH1 or vice versa. The results from this investigation suggest that the S2204I mutation affects HCV RNA replication differentially depending on the viral genotypes but that the effect was not simply explained by the genotypic background. Perhaps, the effect of the S2204I mutation on HCV replication reflects both intra- and intergenic interactions of NS5A protein. J. Med. Virol. 89:146-152, 2017. © 2016 Wiley Periodicals, Inc.
- 8 June 2016
- Published by Wiley in Journal of Medical Virology
- Vol. 89 (1) , 146-152
Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes
Most of HCV RNAs require cell culture-adaptive mutations for efficient replication in cell culture and a number of such mutations have been described including a well-known S2204I substitution mutation in NS5A protein. In contrast, the replication of genotype 2a JFH1 RNA in cell culture does not require any cell culture-adaptive mutation. Rather, the presence of S2204I mutation impaired the JFH1 RNA replication. In this study, we examined the effect of reversions and substitutions of NS5A cell culture-adaptive mutations on virus replication in different genotypic backgrounds after either placing genotype 1a NS5A in the genotype 2a JFH1 or vice versa. The results from this investigation suggest that the S2204I mutation affects HCV RNA replication differentially depending on the viral genotypes but that the effect was not simply explained by the genotypic background. Perhaps, the effect of the S2204I mutation on HCV replication reflects both intra- and intergenic interactions of NS5A protein. J. Med. Virol. 89:146-152, 2017. © 2016 Wiley Periodicals, Inc.
- Open Access
- 2 December 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e113938
Casein Kinase II Inhibitor Enhances Production of Infectious Genotype 1a Hepatitis C Virus (H77S)
Genotype 2a JFH1 virus has substantially contributed to the progress of HCV biology by allowing entire viral life cycle of HCV in cell culture. Using this genotype 2a virus, casein kinase II (CKII) was previously identified as a crucial host factor in virus assembly by phosphorylating NS5A. Since most of the prior studies employed genotype 2a JFH1 or JFH1-based intragenotypic chimera, we used genotype 1a H77S to study virus assembly. CKII inhibition by chemical inhibitors enhanced H77S virus production in contrast to that of JFH1 virus, but genetic inhibition of CKII by siRNA did not change H77S virus titer significantly. The different outcomes from these two approaches of CKII inhibition suggested that nonspecific target kinase of CKII inhibitors plays a role in increasing H77S virus production and both viral and host factors were investigated in this study. Our results emphasize substantial differences among the HCV genotypes that should be considered in both basic research and clinical practices.
- 2 December 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e113938
Open AccessCasein Kinase II Inhibitor Enhances Production of Infectious Genotype 1a Hepatitis C Virus (H77S)
Genotype 2a JFH1 virus has substantially contributed to the progress of HCV biology by allowing entire viral life cycle of HCV in cell culture. Using this genotype 2a virus, casein kinase II (CKII) was previously identified as a crucial host factor in virus assembly by phosphorylating NS5A. Since most of the prior studies employed genotype 2a JFH1 or JFH1-based intragenotypic chimera, we used genotype 1a H77S to study virus assembly. CKII inhibition by chemical inhibitors enhanced H77S virus production in contrast to that of JFH1 virus, but genetic inhibition of CKII by siRNA did not change H77S virus titer significantly. The different outcomes from these two approaches of CKII inhibition suggested that nonspecific target kinase of CKII inhibitors plays a role in increasing H77S virus production and both viral and host factors were investigated in this study. Our results emphasize substantial differences among the HCV genotypes that should be considered in both basic research and clinical practices.